Organization · Venture Studio
82VS
82VS is a Boston-based venture studio affiliated with Alloy Therapeutics, focusing on building biotech companies that develop innovative therapeutics in various disease areas.
Overview
What 82VS does
What 82VS is
82VS is a Boston-based venture studio affiliated with Alloy Therapeutics, focusing on building biotech companies that develop innovative therapeutics in various disease areas.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Studio
- Structured capabilities
- Funder
- Last reviewed
- March 19, 2026
What Venture studio means
A venture studio is an organization that systematically creates new startups by generating or sourcing ideas, validating them, building early products, recruiting founders or operators, providing shared resources, and retaining meaningful equity in the companies it helps create.
Open the glossary entryOfficial channels
Find 82VS elsewhere
Open the official website or a supported primary organization account.
Capability profile
82VS as a funder
Investment thesis
82VS focuses on building capital-efficient, asset-focused drug companies to support the development of innovative treatments in the biotech sector.
Focus narrative
82VS invests primarily in the biotechnology sector, with a strong emphasis on drug discovery and development. The organization prioritizes capital efficiency and leverages its partnership with Alloy Therapeutics to access advanced discovery platforms and services. Their investment focus encompasses various modalities, including antibodies, bispecifics, TCR mimics, and genetic medicines.
Focus and fit
- Regions
- United States
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
Notable companies in the 82VS portfolio include Aakha Biologics, which develops biologics for cancer therapies; Aldebaran Therapeutics, focusing on medicines for genetic ocular diseases; Broadwing Bio, working on antibody therapies for adult vision loss; Cantai, which develops bispecific antibodies for autoimmune diseases; and Voro, creating tumor-activated antibodies for cancer immunotherapy.
Common questions
What to know about 82VS
Upseed classifies 82VS under the Venture Studio organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 19, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.